A Phase 1 Randomized, Double-Blind, Placebo-Controlled, 2-Part Study to Assess the Safety and Tolerability, Pharmacokinetics, And Pharmacodynamics of Single and Multiple Doses of REGN4461 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 19 Nov 2019
Price : $35 *
At a glance
- Drugs REGN-4461 (Primary) ; REGN-4461 (Primary)
- Indications Lipodystrophy; Obesity
- Focus Adverse reactions
- Sponsors Regeneron Pharmaceuticals
- 13 Nov 2019 Planned End Date changed from 6 Oct 2019 to 27 Jan 2020.
- 13 Nov 2019 Planned primary completion date changed from 21 Jun 2019 to 27 Jan 2020.
- 25 May 2018 New trial record